Top

22-04-2024 | Thrombosis

Overall haemostatic potential assay for prediction of outcomes in venous and arterial thrombosis and thrombo-inflammatory diseases

Authors: Julie Wang, Prahlad Ho, Harshal Nandurkar, Hui Yin Lim

Published in: Journal of Thrombosis and Thrombolysis

Abstract

Thromboembolic diseases including arterial and venous thrombosis are common causes of morbidity and mortality globally. Thrombosis frequently recurs and can also complicate many inflammatory conditions through the process of ‘thrombo-inflammation,’ as evidenced during the COVID-19 pandemic. Current candidate biomarkers for thrombosis prediction, such as D-dimer, have poor predictive efficacy. This limits our capacity to tailor anticoagulation duration individually and may expose lower risk individuals to undue bleeding risk. Global coagulation assays, such as the Overall Haemostatic Potential (OHP) assay, that investigate fibrin generation and fibrinolysis, may provide a more accurate and functional assessment of hypercoagulability. We present a review of fibrin’s critical role as a central modulator of thrombotic risk. The results of our studies demonstrating the OHP assay as a predictive biomarker in venous thromboembolism, chronic renal disease, diabetes mellitus, post-thrombotic syndrome, and COVID-19 are discussed. As a comprehensive and global measurement of fibrin generation and fibrinolytic capacity, the OHP assay may be a valuable addition to future multi-modal predictive tools in thrombosis.

Wendelboe AM, Raskob GE (2016) Global Burden of Thrombosis. Circ Res 118:1340–1347. https://doi.org/10.1161/circresaha.115.306841CrossRefPubMed

Khan F, Rahman A, Carrier M et al (2019) Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ (Clinical Res ed) 366:l4363. https://doi.org/10.1136/bmj.l4363CrossRef

Stark K, Massberg S (2021) Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol 18:666–682. https://doi.org/10.1038/s41569-021-00552-1CrossRefPubMedPubMedCentral

Klok FA, Kruip MJHA, Meer NJM, van der et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 191:145–147. https://doi.org/10.1016/j.thromres.2020.04.013CrossRefPubMedPubMedCentral

Tan BK, Mainbourg S, Friggeri A et al (2021) Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax 76:970–979. https://doi.org/10.1136/thoraxjnl-2020-215383CrossRefPubMed

Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH (2013) New fundamentals in Hemostasis. Physiol Rev 93:327–358. https://doi.org/10.1152/physrev.00016.2011CrossRefPubMed

Lim HY, Donnan G, Nandurkar H, Ho P (2022) Global coagulation assays in hypercoagulable states. J Thromb Thrombolys 54:132–144. https://doi.org/10.1007/s11239-021-02621-1CrossRef

Lim HY, O’Malley C, Donnan G et al (2019) A review of global coagulation assays — is there a role in thrombosis risk prediction? Thromb Res 179:45–55. https://doi.org/10.1016/j.thromres.2019.04.033CrossRefPubMed

Eichinger S, Hron G, Kollars M, Kyrle PA (2008) Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin Chem 54:2042–2048. https://doi.org/10.1373/clinchem.2008.112243CrossRefPubMed

10.

Tripodi A, Legnani C, Chantarangkul V et al (2008) High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 6:1327–1333. https://doi.org/10.1111/j.1538-7836.2008.03018.xCrossRefPubMed

11.

Young G, Sørensen B, Dargaud Y et al (2013) Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood 121:1944–1950. https://doi.org/10.1182/blood-2012-08-378935CrossRefPubMedPubMedCentral

12.

Lim HY, Lui B, Tacey M et al (2023) Global coagulation assays in patients with chronic kidney disease and their role in predicting thrombotic risk. Thromb Res 226:127–135. https://doi.org/10.1016/j.thromres.2023.04.016CrossRefPubMed

13.

Wang J, Lim HY, Brook R et al (2022) Overall haemostatic potential (OHP) assay can risk stratify for venous thromboembolism recurrence in anticoagulated patients. J Thromb Thrombolysis 55:32–41. https://doi.org/10.1007/s11239-022-02686-6CrossRefPubMedPubMedCentral

14.

Wang J, Choy KW, Lim HY, Ho P (2022) Impaired fibrinolytic potential predicts Oxygen requirement in COVID-19. J Personalized Med 12:1711. https://doi.org/10.3390/jpm12101711CrossRef

15.

Drake TA, Morrissey JH, Edgington TS (1989) Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 134:1087–1097PubMedPubMedCentral

16.

Mann KG, Brummel-Ziedins K, Orfeo T, Butenas S (2006) Models of blood coagulation. Blood Cells Mol Dis 36:108–117. https://doi.org/10.1016/j.bcmd.2005.12.034CrossRefPubMed

17.

Litvinov RI, Weisel JW (2023) Blood clot contraction: mechanisms, pathophysiology, and disease. Res Pr Thromb Haemost 7:100023. https://doi.org/10.1016/j.rpth.2022.100023CrossRef

18.

Wakefield TW, Myers DD, Henke PK, Arter (2008) Thromb Vasc Biol 28:387–391. https://doi.org/10.1161/atvbaha.108.162289CrossRef

19.

Weisel JW, Litvinov RI (2019) Red blood cells: the forgotten player in hemostasis and thrombosis. J Thromb Haemost 17:271–282. https://doi.org/10.1111/jth.14360CrossRefPubMedPubMedCentral

20.

Weisel JW (2005) Fibrinogen and fibrin. Adv Protein Chem 70:247–299. https://doi.org/10.1016/s0065-3233(05)70008-5CrossRefPubMed

21.

Undas A (2014) Fibrin clot properties and their modulation in thrombotic disorders. Thromb Haemostasis 112:32–42. https://doi.org/10.1160/th14-01-0032CrossRef

22.

Okude M, Yamanaka A, Akihama S (1995) The effects of pH on the generation of turbidity and elasticity Associated with Fibrinogen-Fibrin Conversion by Thrombin are remarkably influenced by Sialic Acid in Fibrinogen. Biol Pharm Bull 18:203–207. https://doi.org/10.1248/bpb.18.203CrossRefPubMed

23.

Nair CH, Shah GA, Dhall DP (1986) Effect of temperature, Ph and ionic strength and composition on fibrin network structure and its development. Thromb Res 42:809–816. https://doi.org/10.1016/0049-3848(86)90117-9CrossRefPubMed

24.

Okada M, Blombäck B (1983) Calcium and fibrin gel structure. Thromb Res 29:269–280. https://doi.org/10.1016/0049-3848(83)90039-7CrossRefPubMed

25.

Carr ME, Dent RM, Carr SL (1996) Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J Lab Clin Med 128:83–88. https://doi.org/10.1016/s0022-2143(96)90116-xCrossRefPubMed

26.

Cines DB, Lebedeva T, Nagaswami C et al (2014) Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. Blood 123:1596–1603. https://doi.org/10.1182/blood-2013-08-523860CrossRefPubMedPubMedCentral

27.

Zubairova LD, Nabiullina RM, Nagaswami C et al (2015) Circulating microparticles alter formation, structure and Properties of Fibrin Clots. Sci Rep-uk 5:17611. https://doi.org/10.1038/srep17611CrossRef

28.

Gould TJ, Vu TT, Stafford AR et al (2018) Cell-free DNA modulates clot structure and impairs Fibrinolysis in Sepsis. Arterioscler Thromb Vasc Biology 35:2544–2553. https://doi.org/10.1161/atvbaha.115.306035CrossRef

29.

Macrae F, Domingues M, Casini A, Ariëns R (2016) The (patho)physiology of Fibrinogen γ′. Seminars Thromb Hemost 42:344–355. https://doi.org/10.1055/s-0036-1572353CrossRef

30.

de Vries JJ, Snoek CJM, Rijken DC, de Maat MPM (2019) Effects of post-translational modifications of fibrinogen on clot formation, clot structure, and Fibrinolysis. Arterioscler Thromb Vasc Biology 40:554–569. https://doi.org/10.1161/atvbaha.119.313626CrossRef

31.

Medcalf RL (2007) Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost 5:132–142. https://doi.org/10.1111/j.1538-7836.2007.02464.xCrossRefPubMed

32.

Cesarman-Maus G, Hajjar KA (2005) Molecular mechanisms of fibrinolysis. Brit J Haematol 129:307–321. https://doi.org/10.1111/j.1365-2141.2005.05444.xCrossRef

33.

Collet JP, Park D, Lesty C et al (2000) Influence of Fibrin Network Conformation and Fibrin Fiber Diameter on Fibrinolysis Speed. Arterioscler Thromb Vasc Biology 20:1354–1361. https://doi.org/10.1161/01.atv.20.5.1354CrossRef

34.

Foley JH, Conway EM (2016) Cross Talk pathways between Coagulation and inflammation. Circ Res 118:1392–1408. https://doi.org/10.1161/circresaha.116.306853CrossRefPubMed

35.

Festa A, D’Agostino R, Tracy RP et al (2002) Elevated Levels of Acute-Phase Proteins and Plasminogen Activator Inhibitor-1 predict the development of type 2 diabetes. Diabetes 51:1131–1137. https://doi.org/10.2337/diabetes.51.4.1131CrossRefPubMed

36.

Okafor ON, Gorog DA (2015) Endogenous fibrinolysis an important mediator of Thrombus formation and Cardiovascular Risk. J Am Coll Cardiol 65:1683–1699. https://doi.org/10.1016/j.jacc.2015.02.040CrossRefPubMed

37.

Spencer FAA Jr. FA (2003) Risk factors for venous thromboembolism. Circulation 107:9I–16. https://doi.org/10.1161/01.cir.0000078469.07362.e6CrossRef

38.

Bruinstroop E, Klok FA, Ree MAVD et al (2009) Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost 7:611–618. https://doi.org/10.1111/j.1538-7836.2009.03293.xCrossRefPubMed

39.

van Es N, Takada T, Kraaijpoel N et al (2023) Diagnostic management of acute pulmonary embolism: a prediction model based on a patient data meta-analysis. Eur Hear J 44:3073–3081. https://doi.org/10.1093/eurheartj/ehad417CrossRef

40.

Tosetto A, Iorio A, Marcucci M et al (2012) Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 10:1019–1025. https://doi.org/10.1111/j.1538-7836.2012.04735.xCrossRefPubMed

41.

Eichinger S, Heinze G, Jandeck LM, Kyrle PA (2010) Risk Assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism. Circulation 121:1630–1636. https://doi.org/10.1161/circulationaha.109.925214CrossRefPubMed

42.

Wang J, Lim HY, Ho P (2021) Individualised risk assessments for recurrent venous thromboembolism: New frontiers in the era of direct oral anticoagulants. Hemato 2:64–78. https://doi.org/10.3390/hemato2010003CrossRef

43.

Weitz JI, Fredenburgh JC, Eikelboom JW (2017) A test in Context: D-Dimer. J Am Coll Cardiol 70:2411–2420. https://doi.org/10.1016/j.jacc.2017.09.024CrossRefPubMed

44.

de Wit K, Al-Haimus F, Hu Y et al (2023) Comparison of YEARS and adjust-unlikely D-dimer testing for Pulmonary Embolism in the Emergency Department. Ann Emerg Med 81:558–565. https://doi.org/10.1016/j.annemergmed.2022.09.014CrossRefPubMed

45.

Palareti G, Cosmi B, Legnani C et al (2014) D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood 124:196–203. https://doi.org/10.1182/blood-2014-01-548065CrossRefPubMed

46.

Khan F, Tritschler T, Kimpton M et al (2021) Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and Meta-analysis. Ann Intern Med 174:1420–1429. https://doi.org/10.7326/m21-1094CrossRefPubMed

47.

Kleinegris M-C, Cate H, ten Cate-Hoek A (2013) D-dimer as a marker for cardiovascular and arterial thrombotic events in patients with peripheral arterial disease. Thromb Haemost 110:233–243. https://doi.org/10.1160/th13-01-0032CrossRefPubMed

48.

Longstaff C (2018) Measuring fibrinolysis: from research to routine diagnostic assays. J Thromb Haemost 16:652–662. https://doi.org/10.1111/jth.13957CrossRefPubMedPubMedCentral

49.

Meltzer ME, Lisman T, de Groot PG et al (2010) Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 116:113–121. https://doi.org/10.1182/blood-2010-02-267740CrossRefPubMed

50.

Belcher HA, Litwa K, Guthold M, Hudson NE (2022) The applicability of current turbidimetric approaches for analyzing fibrin fibers and other Filamentous Networks. Biomolecules 12:807. https://doi.org/10.3390/biom12060807CrossRefPubMedPubMedCentral

51.

He S, Cao H, Thålin C et al (2020) The clotting trigger is an important determinant for the Coagulation pathway in vivo or in Vitro—Inference from Data Review. Semin Thromb Hemost 47:063–073. https://doi.org/10.1055/s-0040-1718888CrossRef

52.

Wolberg AS, Gabriel DA, Hoffman M (2002) Analyzing fibrin clot structure using a microplate reader. Blood Coagul Fibrin 13:533–539. https://doi.org/10.1097/00001721-200209000-00008CrossRef

53.

He S, Bremme K, Blombäck M (1999) A Laboratory Method for determination of overall haemostatic potential in plasma. I. Method Design and preliminary results. Thromb Res 96:145–156. https://doi.org/10.1016/s0049-3848(99)00092-4CrossRefPubMed

54.

Wang J, Lim HY, Nandurkar H, Ho P (2022) Age, sex and racial differences in fibrin formation and fibrinolysis within the healthy population. Blood Coagul Fibrin 33:141–144. https://doi.org/10.1097/mbc.0000000000001115CrossRef

55.

He S, Zhu K, Skeppholm M et al (2007) A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma. Thromb Haemostasis 98:871–882CrossRef

56.

Curnow JL, Morel-Kopp M‐C., Roddie C et al (2007) Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay. J Thromb Haemost 5:528–534. https://doi.org/10.1111/j.1538-7836.2007.02362.xCrossRefPubMed

57.

He S, Antovic A, research MBT (2001) (2001) A simple and rapid laboratory method for determination of haemostasis potential in plasma: II. Modifications for use in routine laboratories and research work. Elsevier 103:355–361. https://doi.org/10.1016/s0049-3848(01)00332-2

58.

Mari D, Ogliari G, Castaldi D et al (2008) Hemostasis and ageing. Immun Ageing 5:12. https://doi.org/10.1186/1742-4933-5-12CrossRefPubMedPubMedCentral

59.

Ferrucci L, Fabbri E (2018) Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 15:505–522. https://doi.org/10.1038/s41569-018-0064-2CrossRefPubMedPubMedCentral

60.

Rosendaal FR, Helmerhorst FM, Vandenbroucke JP (2002) Female hormones and thrombosis. Arterioscler Thromb Vasc Biology 22:201–210. https://doi.org/10.1161/hq0202.102318CrossRef

61.

Kannel WB, D’Agostino RB, Belanger AJ (1992) Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol 2:457–466. https://doi.org/10.1016/1047-2797(92)90095-8CrossRefPubMed

62.

Meijers J, Middeldorp S, Tekelenburg W et al (2000) Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down Regulation of Fibrinolysis. Thromb Haemostasis 84:9–14. https://doi.org/10.1055/s-0037-1613959CrossRef

63.

Arnesen CAL, Veres K, Horváth-Puhó E et al (2022) Estimated lifetime risk of venous thromboembolism in men and women in a Danish nationwide cohort: impact of competing risk of death. Eur J Epidemiol 37:195–203. https://doi.org/10.1007/s10654-021-00813-wCrossRefPubMed

64.

Roy-O’Reilly M, McCullough LD (2014) Sex differences in stroke: the contribution of coagulation. Exp Neurol 259:16–27. https://doi.org/10.1016/j.expneurol.2014.02.011CrossRefPubMedPubMedCentral

65.

McLeod B, Lim HY, Nandurkar H et al (2022) Overall hemostatic potential assay detects risk of progression to post-thrombotic syndrome in anticoagulated patients following deep vein thrombosis. Diagnostics 12:3165. https://doi.org/10.3390/diagnostics12123165CrossRefPubMedPubMedCentral

66.

Lim HY, Lui B, Tacey M et al (2021) Global coagulation assays in patients with diabetes mellitus. Res Pract Thromb Haemostasis 5:e12611. https://doi.org/10.1002/rth2.12611CrossRef

67.

Chow V, Reddel C, Pennings G et al (2015) Persistent global hypercoagulability in long-term survivors of acute pulmonary embolism. Blood Coagul Fibrin 26:537–544. https://doi.org/10.1097/mbc.0000000000000285CrossRef

68.

Antovic A, Blombäck M, Bremme K et al (2003) Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance. J Thromb Haemost 1:2531–2535. https://doi.org/10.1111/j.1538-7836.2003.00451.xCrossRefPubMed

69.

Drabik L, Konieczyńska M, Undas A (2020) Clot lysis time predicts Stroke during Anticoagulant Therapy in patients with Atrial Fibrillation. Can J Cardiol 36:119–126. https://doi.org/10.1016/j.cjca.2019.08.001CrossRefPubMed

70.

Wang J, Lim HY, Nandurkar H, Ho P (2023) DOAC-stop can remove direct oral anticoagulants and allow analysis by global coagulation assays. Int J Lab Hematol. https://doi.org/10.1111/ijlh.14020CrossRefPubMed

71.

Kahn SR (2016) The post-thrombotic syndrome. Hematology 2016:413–418. https://doi.org/10.1182/asheducation-2016.1.413CrossRefPubMedPubMedCentral

72.

Prandoni P (2012) Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants. Eur J Haematol 88:185–194. https://doi.org/10.1111/j.1600-0609.2011.01733.xCrossRefPubMed

73.

Kahn SR, Shapiro S, Wells PS et al (2014) Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet 383:880–888. https://doi.org/10.1016/s0140-6736(13)61902-9CrossRefPubMed

74.

Vedantham S, Goldhaber SZ, Julian JA et al (2017) Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. New Engl J Med 377:2240–2252. https://doi.org/10.1056/nejmoa1615066CrossRefPubMed

75.

Kearon C, Gu C-S, Julian J et al (2019) Pharmacomechanical Catheter-Directed Thrombolysis in Acute femoral–popliteal deep vein thrombosis: analysis from a stratified Randomized Trial. Thromb Haemostasis 119:633–644. https://doi.org/10.1055/s-0039-1677795CrossRef

76.

Kattula S, Byrnes JR, Wolberg AS (2018) Fibrinogen and fibrin in Hemostasis and thrombosis. Arterioscler Thromb Vasc Biology 37:e13–e21. https://doi.org/10.1161/atvbaha.117.308564CrossRef

77.

Sumaya W, Wallentin L, James SK et al (2018) Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. Eur Hear J 39:1078–1085. https://doi.org/10.1093/eurheartj/ehy013CrossRef

78.

Farag M, Spinthakis N, Gue YX et al (2018) Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study. Eur Heart J 40:295–305. https://doi.org/10.1093/eurheartj/ehy656CrossRef

79.

Crowther MA, Roberts J, Roberts R et al (2001) Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemostasis 85:390–394CrossRef

80.

Undas A (2021) Fibrinolysis in venous thromboembolism. Semin Thromb Hemost 47:480–489. https://doi.org/10.1055/s-0041-1725094CrossRefPubMed

81.

Gorog DA, Lip GYH (2019) Impaired Spontaneous/Endogenous fibrinolytic status as New Cardiovascular Risk factor? JACC Review Topic of the Week. J Am Coll Cardiol 74:1366–1375. https://doi.org/10.1016/j.jacc.2019.07.030CrossRefPubMed

82.

Harahsheh Y, Ho KM (2018) Use of viscoelastic tests to predict clinical thromboembolic events: a systematic review and meta-analysis. Eur J Haematol 100:113–123. https://doi.org/10.1111/ejh.12992CrossRefPubMed

83.

Yamamoto J, Yamashita T, Ikarugi H et al (2003) Görög thrombosis test. Blood Coagul Fibrinolysis 14:31–39. https://doi.org/10.1097/01.mbc.0000046170.06450.9bCrossRefPubMed

84.

Edfors F, Iglesias MJ, Butler LM, Odeberg J (2022) Proteomics in thrombosis research. Res Pr Thromb Haemost 6:e12706. https://doi.org/10.1002/rth2.12706CrossRef

85.

Quintero M, Tasic L, Annichino-Bizzacchi JM (2020) Thrombosis: current knowledge based on metabolomics by nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS). Thromb Updat 1:100011. https://doi.org/10.1016/j.tru.2020.100011CrossRef

86.

Atkins CG, Buckley K, Blades MW, Turner RFB (2016) Raman Spectroscopy of Blood and Blood Components. Appl Spectrosc 71:767–793. https://doi.org/10.1177/0003702816686593CrossRef

87.

Blombäck B, Carlsson K, Hessel B et al (1989) Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Et Biophys Acta Bba - Protein Struct Mol Enzym 997:96–110. https://doi.org/10.1016/0167-4838(89)90140-4CrossRef

88.

Hugenholtz GCG, Macrae F, Adelmeijer J et al (2016) Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. J Thromb Haemost 14:1054–1066. https://doi.org/10.1111/jth.13278CrossRefPubMed

89.

Becatti M, Mannucci A, Argento FR et al (2020) Super-resolution Microscopy reveals an altered Fibrin Network in cirrhosis: the key role of oxidative stress in fibrinogen structural modifications. Antioxidants 9:737. https://doi.org/10.3390/antiox9080737CrossRefPubMedPubMedCentral

90.

Bonaventura A, Vecchié A, Dagna L et al (2021) Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol 21:319–329. https://doi.org/10.1038/s41577-021-00536-9CrossRefPubMedPubMedCentral

91.

Investigators A, Investigators A- 4a, Investigators R-C et al (2021) Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. New Engl J Med 385:NEJMoa2105911. https://doi.org/10.1056/nejmoa2105911CrossRef

92.

Spyropoulos AC, Goldin M, Giannis D et al (2021) Efficacy and safety of therapeutic-dose heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk hospitalized patients with COVID-19. Jama Intern Med 181. https://doi.org/10.1001/jamainternmed.2021.6203

93.

Sholzberg M, Tang GH, Rahhal H et al (2021) Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 375:n2400. https://doi.org/10.1136/bmj.n2400CrossRefPubMed

94.

Dronkers CEA, Mol GC, Maraziti G et al (2018) Predicting Post-thrombotic Syndrome with Ultrasonographic Follow-Up after deep vein thrombosis: a systematic review and Meta-analysis. Thromb Haemostasis 118:1428–1438. https://doi.org/10.1055/s-0038-1666859CrossRef

95.

Bergan JJ, Schmid-Schönbein GW, Smith PDC et al (2006) Chronic venous disease. New Engl J Med 355:488–498. https://doi.org/10.1056/nejmra055289CrossRefPubMed

96.

Passerini AG, Milsted A, Rittgers SE (2003) Shear stress magnitude and directionality modulate growth factor gene expression in preconditioned vascular endothelial cells. J Vasc Surg 37:182–190. https://doi.org/10.1067/mva.2003.66CrossRefPubMed

97.

Chandrashekar A, Garry J, Gasparis A, Labropoulos N (2017) Vein wall remodeling in patients with acute deep vein thrombosis and chronic postthrombotic changes. J Thromb Haemost 15:1989–1993. https://doi.org/10.1111/jth.13793CrossRefPubMed

98.

Rabinovich A, Cohen JM, Kahn SR (2015) Predictive value of markers of inflammation in the postthrombotic syndrome: a systematic review inflammatory biomarkers and PTS. Thromb Res 136:289–297. https://doi.org/10.1016/j.thromres.2015.06.024CrossRefPubMed

99.

Bouman AC, Smits JJM, Cate HT, Cate-Hoek AJT (2012) Markers of coagulation, fibrinolysis and inflammation in relation to post‐thrombotic syndrome. J Thromb Haemost 10:1532–1538. https://doi.org/10.1111/j.1538-7836.2012.04798.xCrossRefPubMed

100.

Morrish NJ, Wang S-L, Stevens LK et al (2001) Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 44:S14. https://doi.org/10.1007/pl00002934CrossRefPubMed

101.

Colagiuri S, Lee CMY, Wong TY et al (2011) Glycemic thresholds for Diabetes-Specific Retinopathy. Diabetes Care 34:145–150. https://doi.org/10.2337/dc10-1206CrossRefPubMed

102.

Group AC, Patel A, MacMahon S et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572. https://doi.org/10.1056/nejmoa0802987CrossRef

103.

Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139. https://doi.org/10.1056/nejmoa0808431CrossRefPubMed

104.

Group A to CCR in DS, Gerstein HC, Miller ME et al (2008) Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 358:2545–2559. https://doi.org/10.1056/nejmoa0802743

105.

Kearney K, Tomlinson D, Smith K, Ajjan R (2017) Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. Cardiovasc Diabetol 16:34. https://doi.org/10.1186/s12933-017-0515-9CrossRefPubMedPubMedCentral

106.

Collaborators G C of, Roth D, Abate GA (2017) D, (2018) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1736–1788. https://doi.org/10.1016/s0140-6736(18)32203-7

107.

Lutz J, Menke J, Sollinger D et al (2014) Haemostasis in chronic kidney disease. Nephrol Dial Transpl 29:29–40. https://doi.org/10.1093/ndt/gft209CrossRef

108.

Drawz PE, Baraniuk S, Davis BR et al (2012) Cardiovascular risk assessment: addition of CKD and race to the Framingham equation. Am Hear J 164:925–931e2. https://doi.org/10.1016/j.ahj.2012.09.003CrossRef

109.

Chang A, Kramer H (2011) Should eGFR and Albuminuria be added to the Framingham risk score chronic kidney Disease and Cardiovascular Disease Risk Prediction. Nephron Clin Pr 119:c171–c178. https://doi.org/10.1159/000325669CrossRef

110.

Mackman N, Antoniak S, Wolberg AS et al (2020) Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other Pandemic viruses. Arter Thromb Vasc Biology 40:2033–2044. https://doi.org/10.1161/atvbaha.120.314514CrossRef

111.

Wygrecka M, Birnhuber A, Seeliger B et al (2021) Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19. Blood Adv 6:1074–1087. https://doi.org/10.1182/bloodadvances.2021004816CrossRef

112.

Lee N, Wang J, Brook R et al (2022) The evaluation of overall hemostatic potential assay in patients with COVID-19 infection. Int J Lab Hematol 44:e219–e223. https://doi.org/10.1111/ijlh.13881CrossRefPubMed

Title: Overall haemostatic potential assay for prediction of outcomes in venous and arterial thrombosis and thrombo-inflammatory diseases
Authors: Julie Wang
Prahlad Ho
Harshal Nandurkar
Hui Yin Lim
Publication date: 22-04-2024
Publisher: Springer US
Keywords: Thrombosis
Postthrombotic Syndrome
Biomarkers
Fibrinolytic Therapy
Published in: Journal of Thrombosis and Thrombolysis
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-024-02975-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com